Alliance for Clinical Trials in Oncology
- Country
- πΊπΈUnited States
- Ownership
- Private
- Established
- 2011-01-01
- Employees
- 251
- Market Cap
- -
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Other: Patient ObservationProcedure: Bone Marrow BiopsyOther: Fludeoxyglucose F-18Procedure: Positron Emission TomographyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: ColonoscopyProcedure: EsophagogastroduodenoscopyProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 421
- Registration Number
- NCT05976763
- Locations
- πΊπΈ
Tower Cancer Research Foundation, Beverly Hills, California, United States
πΊπΈCity of Hope Comprehensive Cancer Center, Duarte, California, United States
πΊπΈCity of Hope at Irvine Lennar, Irvine, California, United States
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- Conditions
- Early Stage Triple-Negative Breast CarcinomaAnatomic Stage I Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8
- Interventions
- Other: Patient ObservationProcedure: BiopsyProcedure: Biospecimen CollectionOther: Questionnaire AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1295
- Registration Number
- NCT05812807
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈThomas Hospital, Fairhope, Alabama, United States
πΊπΈMobile Infirmary Medical Center, Mobile, Alabama, United States
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Chemotherapy-Induced Peripheral NeuropathyMetastatic Breast Carcinoma
- Interventions
- Other: Quality-of-life assessmentOther: Questionnaire AdministrationDrug: Placebo Administration
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 98
- Registration Number
- NCT05751668
- Locations
- πΊπΈ
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
πΊπΈUC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
πΊπΈMorton Plant Hospital, Clearwater, Florida, United States
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
- Conditions
- Colon AdenocarcinomaMicrosatellite Stable Colon CarcinomaStage IIB Colon Cancer AJCC V8Stage IIC Colon Cancer AJCC V8Stage III Colon Cancer AJCC V8
- Interventions
- Procedure: Biospecimen CollectionOther: Patient ObservationProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 1
- Registration Number
- NCT05710406
- Locations
- πΊπΈ
Beebe South Coastal Health Campus, Millville, Delaware, United States
πΊπΈHelen F Graham Cancer Center, Newark, Delaware, United States
πΊπΈMedical Oncology Hematology Consultants PA, Newark, Delaware, United States
Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma
- Conditions
- Advanced Dedifferentiated LiposarcomaLocally Advanced Dedifferentiated LiposarcomaMetastatic Dedifferentiated LiposarcomaStage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8Unresectable Dedifferentiated Liposarcoma
- Interventions
- Procedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Biospecimen collectionOther: Questionnaire Administration
- First Posted Date
- 2023-01-23
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 77
- Registration Number
- NCT05694871
- Locations
- πΊπΈ
Henry Ford Macomb Hospital-Clinton Township, Clinton Township, Michigan, United States
πΊπΈFred Hutchinson Cancer Center, Seattle, Washington, United States
πΊπΈUniversity of Washington Medical Center - Montlake, Seattle, Washington, United States
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Conditions
- Advanced Esophageal AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Esophageal Adenocarcinoma
- Interventions
- Procedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: Biospecimen CollectionOther: Questionnaire Administration
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 382
- Registration Number
- NCT05677490
- Locations
- πΊπΈ
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
πΊπΈAnchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
πΊπΈAnchorage Radiation Therapy Center, Anchorage, Alaska, United States
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
- Conditions
- Advanced Uveal MelanomaMetastatic Uveal MelanomaUnresectable Uveal Melanoma
- Interventions
- Drug: BRD4 Inhibitor PLX2853Procedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Biospecimen collection
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Registration Number
- NCT05677373
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
- Conditions
- Metastatic Colorectal AdenocarcinomaStage IV Colorectal Cancer AJCC v8
- Interventions
- Procedure: Stereotactic Ablative RadiotherapyProcedure: ResectionProcedure: Microwave AblationDrug: ChemotherapyProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 364
- Registration Number
- NCT05673148
- Locations
- πΊπΈ
Jupiter Medical Center, Jupiter, Florida, United States
πΊπΈUI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United States
πΊπΈUI Health Care Mission Cancer and Blood - West Des Moines Clinic, Clive, Iowa, United States
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
- Conditions
- Pleural Biphasic MesotheliomaPleural Sarcomatoid Mesothelioma
- Interventions
- Procedure: Surgical ProcedureProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission Tomography
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05647265
- Locations
- πΊπΈ
Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
πΊπΈAnchorage Radiation Therapy Center, Anchorage, Alaska, United States
πΊπΈAlaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation
- Conditions
- Locally Advanced Rectal CarcinomaStage II Rectal Cancer AJCC v8Stage III Rectal Cancer AJCC v8
- Interventions
- Radiation: Long Course ChemoradiotherapyProcedure: Magnetic Resonance ImagingProcedure: Computed TomographyProcedure: SigmoidoscopyProcedure: biopsy
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 312
- Registration Number
- NCT05610163
- Locations
- πΊπΈ
Keck Medicine of USC Buena Park, Buena Park, California, United States
πΊπΈUSC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
πΊπΈSaint Helena Hospital, Saint Helena, California, United States